Eyenuk vs RapidAI

Eyenuk and RapidAI sell into different departments. EyeArt grades diabetic retinopathy from retinal photographs and returns a DR level plus a report that the vendor says needs no physician overread, so a primary care clinic running diabetic eye screens can use it at the point of care without a specialist. The FAQ cites CPT 92229 for US reimbursement and states no per-patient or subscription price.

RapidAI is licensed at hospital level for stroke programs. Rapid LVO was cleared as K200941 on July 9, 2020 under product code QAS, and the platform adds perfusion, ASPECTS and ICH modules on CT. The DUEL study, promoted by RapidAI and reported by NeurologyLive from AJNR in May 2026, covered about 1,590 code strokes and found 98% of confirmed LVOs detected by Rapid LVO.ai. It was retrospective and single-center.